Lymphopenia and elevated NLR identify patients with septic shock who may benefit from corticosteroids: a target trial emulation study
Patrick Jason Toppin, Mario Diego Teles Correia, Yale Chang, Lasith Adhikari, Brian McLaverty, Annamalai Natarajan · 2026
Read Lymphopenia and elevated NLR identify patients with septic shock who may benefit from corticosteroids: a target trial emulation study by Patrick Jason Toppin, Mario Diego Teles Correia, Yale Chang, Lasith Adhikari, Brian McLaverty, Annamalai Natarajan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13624219.txt.
Description
Patrick Jason Toppin leads a study asking which patients in septic shock actually gain from corticosteroid treatment, a cheap drug whose overall benefit has stayed murky for decades. Rather than run a new trial, the team emulated one inside a large intensive care database, comparing similar patients who did or did not receive the drugs.
The analysis covered 5,533 septic shock stays, about eighteen percent of them steroid-treated, and those patients were clearly sicker at the start. After statistical adjustment for that imbalance, simple blood-count patterns flagged who benefited. Patients starting with few infection-fighting lymphocytes, or with high ratios of other white cells to lymphocytes, showed lower intensive care deaths when given steroids. The signals were modest, roughly matching the power of a standard severity score. Because the tests cost almost nothing and exist everywhere, the authors suggest they could help target treatment where resources are scarce.
Catalog record
| CREATOR | Patrick Jason Toppin, Mario Diego Teles Correia, Yale Chang, Lasith Adhikari, Brian McLaverty, Annamalai Natarajan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 50 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |